In the rapidly advancing field of peptide-based drug discovery, few c by LS Gold · 2025 · Cited by 14 — The first targeted oral peptide designed to selectively inhibit interleukin (IL)-23 signaling by blocking the IL-23 receptor on human immune cells. ompounds have captured the attention of researchers and industry observers quite like the PN 235 peptide. As someone who closely follows the evolution of specialized chemical entities, I have observed how this specific molecule—later identified as JNJ-2113 and now known by its generic name, Icotrokinra—represents a significant milestone in oral delivery technology.
The Scientific Significance of PN 235
When we discuss PN 235, we are looking at a milestone in molecular engineering. Historically, the challenge with peptides has always been their stability and bioavailability when administered orally. The development of PN-235—a macrocyclic peptide—changed the landscape by demonstrating that it is possible to design molecules that remain stable within the gastrointestinal tract while maintaining high target specificity.
The primary function of this molecule is to selectively block the interleukin (IL)-23 receptor. By interacting with this specific pathway, the molecule aims to selectively inhibit interleukin (IL)-23 signaling, which is a critical mechanism in various immune-mediated conditions. Unlike earlier iterations such as PTG-200—where PTG-200 is an oral peptide interleukin-23 receptor (IL-23R) antagonist—the transition to the JNJ-77242113 (formerly PN-235) platform marked a substantial increase in potency.
From Discovery to Clinical Progress
My interest in this field began when PN-235 has shown promise in earlier stages of testing, particularly during its Phase 1 trials. Witnessing the progression of this entity has been a masterclass in pharmaceutical development. For those tracking the timing of icotrokinra (JNJ-2113, formerly PN-235), it is clear that the Nov 3, 2020 — PTG-200 is an oral peptide interleukin-23 receptor (IL-23R) antagonist being co-developed with Janssen for the treatment of inflammatory bowel collaboration between Protagonist Therapeutics and Janssen has been instrumental.
The data surrounding JNJ-2113 (formerly PN-235) has been consistently robust. During the early development phases, it was widely discussed that PN-235 is expected to advance into Phase 2 studies in psoriasis, a goal that was successfully met and surpassed. This progression highlights the viability of macrocyclic structures in creating "first-in-class" therapeutics.
Comparative Analysis: PN Series and Beyond
It is helpful to distinguish between the different assets in this pipeline to appr by J Halladay · 2025 — Here we report for the first time the preclinical characterization of PN-881, an orally delivered macrocyclic peptide that potently and selectively binds IL-17A eciate the innovation. While PN-235 focused on the IL-23 pathway, newer developments like PN-881 have emerged to target the IL-17 pathway. This modular approach to drug design—using a flexible, synthetic backbone—allows researchers to pivot between targets with high precision.
When reviewing the 235 serie Protagonist Introduces Oral Peptide IL-17 Antagonist PN-881 s, one must acknowledge the technical precision required to stabilize these chains. The PN designation has become synonymous with high-quality, orally bioavailable research tools. Whether discussing the structural nuances Press Release Protagonist Therapeutics Announces the of the JNJ-77242113 (formerly PN-235) or the broader implications for peptides in the future, the industry is clearly moving toward more targeted, patient-friendly delivery methods.
Final Reflections
As an observer of these advancements, the trajectory of the PN 235 peptide serves as a testament to the power of targeted molecular design. By focusing on the IL-23 receptor, this class of molecules has provided invaluable insights into how we can modulate biological pathways without the need for invasive delivery methods.
For those interested in the future of this space, keeping an eye on the transition from JNJ-2113 (formerly PN-235) to i Dec 17, 2020 — The phase I study on PN-235 will be categorized in three parts, namely – a single ascending dose, a multiple ascending dose and a randomized, ts current clinical status provides a clear roadmap of how rigorous te May 24, 2021 — PTG-200 is an orally delivered, gut-restricted, interleukin-23 receptor specific antagonist peptide in a Phase 2 clinical trial for Crohn's sting and innovative chemistry can redefine the standards of modern biotechnology. The success of this molecule continues to pave the way for a new generation of oral therapeutic candidates.